Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial.
metastatic colorectal cancer
repeated events
selection bias
sequential trial
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
09
2019
accepted:
27
05
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
6
8
2020
Statut:
epublish
Résumé
Cancer trials involving multiple treatment lines substantially increase our understanding of therapeutic strategies. However, even when the primary end-point of these studies is progression-free survival (PFS), their statistical analysis usually focuses on each line separately, or does not consider repeated events, thus missing potentially relevant information. Consequently, the evaluation of the effectiveness of treatment strategies is highly impaired. We evaluated the potentially different effect of bevacizumab (B) administered for the first- or second-line treatment of metastatic colorectal cancer (mCRC) in the ITACa (Italian Trial in Advanced Colorectal Cancer) randomized trial. The ITACa trial consisted of two arms: first-line chemotherapy (CT)+B followed by second-line CT alone The overall effect of B across the two lines resulted in a HR = 0.80 (95% CI 0.68-0.95, Our results seem to suggest that B confers a PFS advantage when administered in combination with second-line chemotherapy, which could help to improve current international guidelines on optimal sequential treatment strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer trials involving multiple treatment lines substantially increase our understanding of therapeutic strategies. However, even when the primary end-point of these studies is progression-free survival (PFS), their statistical analysis usually focuses on each line separately, or does not consider repeated events, thus missing potentially relevant information. Consequently, the evaluation of the effectiveness of treatment strategies is highly impaired.
METHODS
METHODS
We evaluated the potentially different effect of bevacizumab (B) administered for the first- or second-line treatment of metastatic colorectal cancer (mCRC) in the ITACa (Italian Trial in Advanced Colorectal Cancer) randomized trial. The ITACa trial consisted of two arms: first-line chemotherapy (CT)+B followed by second-line CT alone
RESULTS
RESULTS
The overall effect of B across the two lines resulted in a HR = 0.80 (95% CI 0.68-0.95,
CONCLUSION
CONCLUSIONS
Our results seem to suggest that B confers a PFS advantage when administered in combination with second-line chemotherapy, which could help to improve current international guidelines on optimal sequential treatment strategies.
Identifiants
pubmed: 32754229
doi: 10.1177/1758835920937427
pii: 10.1177_1758835920937427
pmc: PMC7378711
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920937427Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Lancet Oncol. 2013 Oct;14(11):1077-1085
pubmed: 24028813
Lancet Oncol. 2016 Oct;17(10):1426-1434
pubmed: 27575024
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
J Clin Oncol. 2007 Apr 20;25(12):1539-44
pubmed: 17442997
Stat Med. 2006 Oct 30;25(20):3518-33
pubmed: 16345026
J Clin Oncol. 2004 Jan 15;22(2):229-37
pubmed: 14657227
J Clin Oncol. 2015 Apr 1;33(10):1112-8
pubmed: 25691669
J Clin Oncol. 2019 May 10;37(14):1217-1227
pubmed: 30865548
BMJ. 2001 Jan 27;322(7280):226-31
pubmed: 11159626
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
J Clin Oncol. 2010 Nov 1;28(31):4697-705
pubmed: 20921465
Lancet Oncol. 2011 Oct;12(11):1032-44
pubmed: 21903473
Lancet Oncol. 2015 May;16(5):499-508
pubmed: 25877855
Ann Oncol. 2015 Apr;26(4):724-730
pubmed: 25600568
J Clin Oncol. 2009 Feb 10;27(5):672-80
pubmed: 19114685
Ann Oncol. 2015 Jun;26(6):1201-1207
pubmed: 25735317
Eur J Cancer. 2013 May;49(8):1882-8
pubmed: 23490654
Sci Rep. 2017 Sep 5;7(1):10426
pubmed: 28874797
J Clin Oncol. 2012 Oct 1;30(28):3499-506
pubmed: 22949147
Ther Adv Med Oncol. 2015 May;7(3):153-69
pubmed: 26673925
Lancet Oncol. 2013 Jan;14(1):29-37
pubmed: 23168366
BMC Cancer. 2015 Jul 04;15:496
pubmed: 26141683
Eur J Cancer. 2017 Sep;83:106-115
pubmed: 28735067
N Engl J Med. 2009 Feb 5;360(6):563-72
pubmed: 19196673
J Clin Oncol. 2008 Apr 20;26(12):2013-9
pubmed: 18421054
Epidemiology. 2000 Sep;11(5):561-70
pubmed: 10955409